Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?

Background and Objectives: Long-acting somatostatin analogues (SSA) (octreotide LAR and lanreotide Autogel) are recommended as first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of these...

Descripción completa

Detalles Bibliográficos
Autores principales: Sowa-Staszczak, Anna, Opalińska, Marta, Kurzyńska, Anna, Morawiec-Sławek, Karolina, Gilis-Januszewska, Aleksandra, Palen-Tytko, Joanna, Olearska, Helena, Hubalewska-Dydejczyk, Alicja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708475/
https://www.ncbi.nlm.nih.gov/pubmed/34946232
http://dx.doi.org/10.3390/medicina57121287

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708475/
https://www.ncbi.nlm.nih.gov/pubmed/34946232
http://dx.doi.org/10.3390/medicina57121287

Ejemplares similares